Christopher Potter

ISPE CMC Pharmaceutical Consultant
Chris Potter graduated from the University of Exeter with a degree in chemistry and completed a PhD at Imperial College London University in organic chemistry. He started work at Beecham Research Laboratories, and moved to Sterling-Winthrop to take management positions in both pharmaceutical and analytical development. During this period he worked on both ethical and over-the-counter drug development. For the later period of his career, Potter moved to ICI Pharmaceuticals, later Zeneca, then AstraZeneca where he had a senior position as manager of Analytical Development and R&D QA and CMC Project Management Group with responsibility in both the UK and US. He finished his career as Director of External Pharmaceutical Programmes. Potter retired at the end of October 2007 and is now performing part-time CMC consultancy work. He is currently part time Technical Project Manager for ISPE's PQLI Program. Potter was a member of EFPIA's ad hoc Quality Group from 1996 to 2007, and during this period was EFPIA topic leader for ICHQ6A, Specifications for New Drug Substances and New Drug Products, and ICH Q4B, Regulatory Acceptance of Pharmacopoeial Interchangeability. Potter led EFPIA's PAT Topic Group, which produced a Mock P2 to promote discussion and understanding regarding how ICH topics Q8 and ICH Q9 could be implemented.

Related Articles

AAAA framework
iSpeak Blog
ISPE Initiatives Support Supply Chain Resiliency

ISPE is a global industry leader in scientific, technical, and regulatory advancement throughout the entire pharmaceutical lifecycle. As a result, ISPE is in a strong position and available to assist the US government, its allies, and like-minded regulatory partners with implementation of recommendations emerging from a report,

Submission and review process diagram
Features
ICH Quality Guidelines: Present Initiatives & ISPE Involvement

In its 30-year history, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) has covered a wide range of topics to generate quality, safety, efficacy, and multidisciplinary harmonized guidelines. As science advances, issued guidelines are being updated and new guidelines are proposed in a pipeline of potential future activity. This...

Quality Risk Management: Ensuring Shared Responsibility across Key Stakeholders
iSpeak Blog
Quality Risk Management: Ensuring Shared Responsibility across Key Stakeholders

ISPE’s second virtual Global Pharmaceutical Regulatory Summit, held on 16 June 2021, brought together regulators from European Medicines Agency (EMA), Australian Therapeutic Goods Administration (TGA), US Food and Drug Administration, and Center for Drug Regulation and Research, FDA Philippines to share their insights on application of quality risk management. They discussed the positive...